All In Biotech

Drug Trial Radar · NCT06963021

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

May 30, 2025

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
May 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Conditions

  • Major Depressive Disorder

Interventions

  • OsavampatorDrug

    Osavampator tablets

  • PlaceboDrug

    Matching placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56Time frame: Baseline, Day 56

Locations

39 sites in 7 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Chino, California · Recruiting

  • Neurocrine Clinical Site

    Los Angeles, California · Recruiting

  • Neurocrine Clinical Site

    Stanford, California · Recruiting

  • Neurocrine Clinical Site

    Aurora, Colorado · Recruiting

  • Neurocrine Clinical Site

    Cromwell, Connecticut · Active not recruiting

  • Neurocrine Clinical Site

    Farmington, Connecticut · Active not recruiting

  • Neurocrine Clinical Site

    Maitland, Florida · Recruiting

  • Neurocrine Clinical Site

    Miami, Florida · Recruiting

  • Neurocrine Clinical Site

    Tampa, Florida · Withdrawn

  • Neurocrine Clinical Site

    Skokie, Illinois · Recruiting

  • Neurocrine Clinical Site

    Gaithersburg, Maryland · Active not recruiting

  • Neurocrine Clinical Site

    Las Vegas, Nevada · Recruiting

  • Neurocrine Clinical Site

    Las Vegas, Nevada · Recruiting

  • Neurocrine Clinical Site

    Cherry Hill, New Jersey · Recruiting

  • Neurocrine Clinical Site

    Cedarhurst, New York · Recruiting

  • Neurocrine Clinical Site

    New York, New York · Active not recruiting

  • Neurocrine Clinical Site

    New York, New York · Recruiting

  • Neurocrine Clinical Site

    Charlotte, North Carolina · Recruiting

  • Neurocrine Clinical Site

    Philadelphia, Pennsylvania · Recruiting

  • Neurocrine Clinical Site

    Alken, Belgium · Active not recruiting

  • Neurocrine Clinical Site

    Bruges, Belgium · Recruiting

  • Neurocrine Clinical Site

    Mechelen, Belgium · Recruiting

  • Neurocrine Clinical Site

    Verdun, Canada · Recruiting

  • Neurocrine Clinical Site

    Toronto, Ontario, Canada · Recruiting

  • Neurocrine Clinical Site

    Kuopio, Finland · Recruiting

  • Neurocrine Clinical Site

    Oulu, Finland · Recruiting

  • Neurocrine Clinical Site

    Tampere, Finland · Recruiting

  • Neurocrine Clinical Site

    Budapest, Hungary · Recruiting

  • Neurocrine Clinical Site

    Budapest, Hungary · Recruiting

  • Neurocrine Clinical Site

    Budapest, Hungary · Recruiting

  • Neurocrine Clinical Site

    Gyöngyös, Hungary · Recruiting

  • Neurocrine Clinical Site

    Kalocsa, Hungary · Active not recruiting

  • Neurocrine Clinical Site

    Jelgava, Latvia · Recruiting

  • Neurocrine Clinical Site

    Liepāja, Latvia · Recruiting

  • Neurocrine Clinical Site

    Sigulda, Latvia · Recruiting

  • Neurocrine Clinical Site

    London, United Kingdom · Recruiting

  • Neurocrine Clinical Site

    Salford, United Kingdom · Recruiting

  • Neurocrine Clinical Site

    Sheffield, United Kingdom · Recruiting

  • Neurocrine Clinical Site

    Southampton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.